Tebipenem tablet form
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioavailability
Conditions
Relative Bioavailability
Trial Timeline
Apr 1, 2022 → Dec 23, 2022
NCT ID
NCT05296382About Tebipenem tablet form
Tebipenem tablet form is a phase 1 stage product being developed by Spero Therapeutics for Relative Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT05296382. Target conditions include Relative Bioavailability.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05296382 | Phase 1 | Completed |
Competing Products
6 competing products in Relative Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab + Sonelokimab | MoonLake Immunotherapeutics | Phase 1 | 28 |
| ABT-333 | AbbVie | Phase 1 | 33 |
| BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg | AstraZeneca | Phase 1 | 33 |
| D1400147 + D14000136 + D14000137 + Epanova® | AstraZeneca | Phase 1 | 33 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 82 |
| Sulfatinib T capsule + Sulfatinib R capsule | HUTCHMED | Phase 1 | 28 |